Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Free Report) and Exicure (NASDAQ:XCUR – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, dividends and analyst recommendations.
Profitability
This table compares Aurinia Pharmaceuticals and Exicure’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aurinia Pharmaceuticals | 97.68% | 22.99% | 17.99% |
| Exicure | N/A | -237.91% | -61.98% |
Risk and Volatility
Aurinia Pharmaceuticals has a beta of 1.4, suggesting that its stock price is 40% more volatile than the S&P 500. Comparatively, Exicure has a beta of 3.83, suggesting that its stock price is 283% more volatile than the S&P 500.
Institutional and Insider Ownership
36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. Comparatively, 42.8% of Exicure shares are owned by institutional investors. 10.4% of Aurinia Pharmaceuticals shares are owned by company insiders. Comparatively, 52.8% of Exicure shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Aurinia Pharmaceuticals and Exicure, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aurinia Pharmaceuticals | 0 | 3 | 3 | 1 | 2.71 |
| Exicure | 1 | 0 | 0 | 0 | 1.00 |
Aurinia Pharmaceuticals currently has a consensus target price of $18.25, indicating a potential upside of 11.59%. Given Aurinia Pharmaceuticals’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Aurinia Pharmaceuticals is more favorable than Exicure.
Earnings & Valuation
This table compares Aurinia Pharmaceuticals and Exicure”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aurinia Pharmaceuticals | $283.05 million | 7.74 | $287.20 million | $2.29 | 7.14 |
| Exicure | N/A | N/A | -$4.95 million | ($1.32) | -0.69 |
Aurinia Pharmaceuticals has higher revenue and earnings than Exicure. Exicure is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Aurinia Pharmaceuticals beats Exicure on 11 of the 14 factors compared between the two stocks.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
About Exicure
Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
